|
|
Volumn 10, Issue 5, 2014, Pages 259-
|
|
A new therapeutic approach for APS?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA2 GLYCOPROTEIN 1 ANTIBODY;
CH2 DELETED VARIANT ANTIBODY;
IMMUNOGLOBULIN G;
LIPOPOLYSACCHARIDE;
PHOSPHOLIPID ANTIBODY;
UNCLASSIFIED DRUG;
BETA2 GLYCOPROTEIN I D1 ANTIBODY;
AUTOANTIGEN;
BETA2 GLYCOPROTEIN 1;
COMPLEMENT;
MONOCLONAL ANTIBODY;
ANTIGEN BINDING;
ANTIPHOSPHOLIPID SYNDROME;
BINDING AFFINITY;
BIOENGINEERING;
COMPLEMENT ACTIVATION;
DISEASE MODEL;
DRUG EFFECT;
ENZYME LINKED IMMUNOSORBENT ASSAY;
FETUS WASTAGE;
HUMAN;
NONHUMAN;
NOTE;
PREGNANCY OUTCOME;
PRIORITY JOURNAL;
PROTEIN DOMAIN;
THROMBOSIS;
TREATMENT OUTCOME;
BLOOD CLOTTING;
FETUS WEIGHT;
ANIMAL;
IMMUNOLOGY;
MALE;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIPHOSPHOLIPID SYNDROME;
AUTOANTIGENS;
BETA 2-GLYCOPROTEIN I;
COMPLEMENT SYSTEM PROTEINS;
HUMANS;
MALE;
|
|
EID: 84899977862
PISSN: 17594790
EISSN: 17594804
Source Type: Journal
DOI: 10.1038/nrrheum.2014.59 Document Type: Note |
|
Times cited : (1)
|
|
References (1)
|
